ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Regeneron Pharmaceuticals is working with Bayer HealthCare to develop an antibody to the platelet-derived growth factor receptor β (PDGFR-β). The partners want to combine it with Regeneron’s eye drug Eylea, which inhibits vascular endothelial growth factor, as a treatment for wet age-related macular degeneration. Bayer will pay $26 million up front, up to $40 million in milestone payments, and share development costs. Separately, Regeneron has launched a human genetics initiative to define disease targets. Its new Regeneron Genetics Center subsidiary will collaborate with the Geisinger Health System of Pennsylvania and NIH’s National Human Genome Research Institute.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter